# Prostate cancer

Source: https://onco.cc/cancers/prostate/  
OnCo record `prostate` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype.

## Summary

Prostate cancer is the most common cancer in men in most high-income countries and a spectrum: most PSA-detected disease is indolent and safely watched (ProtecT: ~3% prostate-cancer mortality at 15 years whatever the strategy), while de novo metastatic disease, treated with hormonal doublets and triplets and since 2026 with radioligand therapy added, still has a median survival of about five years, which makes it the second most common cause of cancer death in men. Diagnosis now runs PSA → multiparametric MRI (PRECISION) → targeted biopsy → Grade Group, with germline and somatic HRR testing for advanced disease and PSMA PET for staging (proPSMA) and recurrence. Digital-pathology AI (ArteraAI Prostate, 2025) and gene-expression classifiers (Decipher) refine who needs treatment and who benefits from adding hormone therapy.

Treatment is built on androgen deprivation, the first targeted cancer therapy (Huggins, 1941). Metastatic hormone-sensitive disease is treated with doublets (ADT + abiraterone, enzalutamide, apalutamide or darolutamide) or triplets adding docetaxel (ARASENS, PEACE-1), and since 31 July 2026 with 177Lu-PSMA-617 added to ADT + ARPI (PSMAddition, rPFS HR 0.72). PTEN-deficient disease gained capivasertib + abiraterone in 2026. In castration-resistant disease the sequence includes ARPI switch, PARP inhibitors for HRR-mutant tumours (PROfound, PROpel, TALAPRO-2 with OS benefit), docetaxel and cabazitaxel, radium-223 for bone-only disease, and 177Lu-PSMA-617 before or after chemotherapy (VISION, PSMAfore). Enzalutamide is approved even for high-risk PSA-only recurrence (EMBARK).

Prostate cancer is the proving ground for theranostics: PSMA PET selects and PSMA radioligands treat. Competing 177Lu-PSMA-I&T products (SPLASH, ECLIPSE) have improved progression but not yet survival; alpha-emitting 225Ac-PSMA agents are in phase 3 (AlphaBreak, AcTION) and produce responses after lutetium failure. T-cell engagers against STEAP1 (xaluritamig, XALute) and KLK2 (pasritamig) are the first immunotherapies with real activity in a disease that ignores checkpoint inhibitors; EZH2 inhibition (mevrometostat, MEVPRO) aims to re-sensitise to hormonal therapy. The unsolved problems are neuroendocrine transformation, AR-V7-driven resistance (the N-terminal-domain inhibitor masofaniten failed), Ac-225 supply, and the over- versus under-diagnosis tension in screening.

## Fields

- Kind: Cancer
- Last checked: 2026-09-06
- Tags: gu; spike
- Group: genitourinary
- Burden: ~1.5 million new cases per year worldwide; lifetime risk ~1 in 8 men in high-income countries; median age at diagnosis 67; most PSA-detected disease is indolent and safely watched. ~400,000 deaths per year worldwide, mostly from disease that was already metastatic at diagnosis.
- Subtypes: Localised: low / favourable-intermediate / unfavourable-intermediate / high risk (NCCN); Non-metastatic castration-resistant (nmCRPC); Metastatic hormone-sensitive (mHSPC; FDA 2026 term 'androgen pathway modulation-naive or -sensitive'), de novo vs recurrent, high vs low volume (CHAARTED); Metastatic castration-resistant (mCRPC); HRR-mutant (~20-25% of mCRPC; BRCA2 most actionable); PTEN-deficient (~25%); PSMA-low / heterogeneous (~10%); Treatment-emergent neuroendocrine prostate cancer (~15-20% of late mCRPC); Ductal and intraductal / cribriform variants (aggressive)
- Biomarkers: PSA; Gleason / Grade Group; PSMA PET; HRR genes (BRCA2, ATM, etc.); PTEN; MSI; AR-V7 (research); Decipher / ArteraAI; PSA, PSA density, PSA doubling time; Grade Group (Gleason) and cribriform/intraductal pattern; mpMRI PI-RADS score; PSMA PET (SUVmax, total tumour volume) for staging and radioligand eligibility; Germline and somatic HRR genes (BRCA2, BRCA1, ATM, PALB2, CDK12); PTEN loss (IHC or NGS) for capivasertib; MSI/dMMR (~3%, pembrolizumab); Decipher genomic classifier; ArteraAI digital pathology; AR-V7 (CTC) in research/limited use; Testosterone level (castration confirmation); Neuroendocrine markers (chromogranin, synaptophysin, RB1/TP53 loss) on progression

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/prostate/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/prostate/#overview [8 subtypes, 9 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/prostate/#what-it-is [17 subtypes, 5 sites of spread]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/prostate/#finding-it [19 biomarkers, 15 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/prostate/#treating-it [11 settings, 5 regimens, 11 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/prostate/evidence/ [241 trials, 10 key papers, 23 milestones]
- The science (own page): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/prostate/science/ [207 targets, 14 pathways, 10 preclinical models]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/prostate/where-you-are/ [67 centres]
- Living with it (own page): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/prostate/living-with-it/ [38 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/prostate/coming/ [84 medicines, 241 trials, 61 ideas, 11 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/prostate/data/ [1028 connected records]

## Standard of care

- Localised: Active surveillance, prostatectomy, or radiation ± ADT (duration guided by risk/ArteraAI). ([Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [MRI](https://onco.cc/technologies/mri/))
- Metastatic hormone-sensitive: ADT + ARPI ± docetaxel; PSMA PET staging; capivasertib if PTEN-deficient. ([Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Capivasertib](https://onco.cc/drugs/capivasertib/))
- Castration-resistant: ARPI switch, PARP inhibitor combinations (HRR+), 177Lu-PSMA-617, docetaxel/cabazitaxel, radium-223. ([Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [Olaparib](https://onco.cc/drugs/olaparib/), [Niraparib](https://onco.cc/drugs/niraparib/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [VISION](https://onco.cc/trials/vision/), [PSMAfore](https://onco.cc/trials/psmafore/))
- Screening: Shared-decision PSA testing from 50 (45 if Black or family history/BRCA), risk-adapted intervals; MRI before biopsy; avoid biopsy if MRI negative and PSA density low. ([PSA (prostate-specific antigen)](https://onco.cc/terms/psa/), [Multiparametric prostate MRI (PI-RADS)](https://onco.cc/technologies/mp-mri/), [PRECISION](https://onco.cc/trials/precision-mri/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/))
- Localised, low / favourable-intermediate risk: Active surveillance (PSA, MRI, repeat biopsy) for Grade Group 1 and many favourable GG2; genomic classifier or ArteraAI to refine. ([Active surveillance](https://onco.cc/technologies/active-surveillance/), [ProtecT](https://onco.cc/trials/protect/), [Decipher Prostate](https://onco.cc/drugs/decipher-prostate/), [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/))
- Localised, unfavourable-intermediate / high risk: Radical prostatectomy (robotic) or radiotherapy (hypofractionated IMRT, SBRT, or brachytherapy boost) with 4-6 months (intermediate) to 18-36 months (high risk) of ADT; abiraterone added for very high risk (STAMPEDE); ArteraAI predicts ADT benefit. ([Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [STAMPEDE](https://onco.cc/trials/stampede/))
- Biochemical recurrence: PSMA PET to localise; salvage radiotherapy ± ADT after prostatectomy; metastasis-directed SBRT for oligorecurrence (investigational for survival); enzalutamide ± ADT for high-risk BCR (EMBARK). ([PSMA PET](https://onco.cc/technologies/psma-pet/), [Biochemical recurrence (BCR)](https://onco.cc/terms/biochemical-recurrence/), [EMBARK](https://onco.cc/trials/embark/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer](https://onco.cc/ideas/idea-psma-pet-guided-mdt/))
- Metastatic hormone-sensitive (mAPMN/S): ADT (GnRH agonist/antagonist, e.g., relugolix) + ARPI (abiraterone, enzalutamide, apalutamide, or darolutamide); add docetaxel for high-volume de novo disease (ARASENS, PEACE-1); add 177Lu-PSMA-617 if PSMA-positive (PSMAddition, approved 31 Jul 2026); capivasertib + abiraterone if PTEN-deficient (2026); prostate RT for low-volume disease. ([Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [Darolutamide](https://onco.cc/drugs/darolutamide/), [Relugolix](https://onco.cc/drugs/relugolix/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [ARASENS](https://onco.cc/trials/arasens/), [PEACE-1](https://onco.cc/trials/peace-1/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [PSMAddition](https://onco.cc/trials/psmaddition/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [CAPItello-281](https://onco.cc/trials/capitello-281/))
- Non-metastatic CRPC: Apalutamide, enzalutamide, or darolutamide (SPARTAN, PROSPER, ARAMIS); PSMA PET usually reclassifies as metastatic. ([Apalutamide](https://onco.cc/drugs/apalutamide/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Darolutamide](https://onco.cc/drugs/darolutamide/), [PSMA PET](https://onco.cc/technologies/psma-pet/))
- Metastatic CRPC, first line: ARPI (if not used earlier); PARP inhibitor + ARPI for BRCA/HRR-mutant (olaparib-abiraterone, talazoparib-enzalutamide, niraparib-abiraterone); docetaxel; 177Lu-PSMA-617 after one ARPI before chemotherapy (PSMAfore); pembrolizumab if MSI-high. ([Olaparib](https://onco.cc/drugs/olaparib/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [Niraparib](https://onco.cc/drugs/niraparib/), [PROpel](https://onco.cc/trials/propel/), [TALAPRO-2](https://onco.cc/trials/talapro-2/), [MAGNITUDE](https://onco.cc/trials/magnitude/), [PROfound](https://onco.cc/trials/profound/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [PSMAfore](https://onco.cc/trials/psmafore/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/))
- Metastatic CRPC, later lines: 177Lu-PSMA-617 post-taxane (VISION); cabazitaxel (CARD); radium-223 for bone-only symptomatic disease (with bone protection); 225Ac-PSMA, xaluritamig, pasritamig, mevrometostat in trials; platinum-etoposide for neuroendocrine transformation; tarlatamab/I-DXd trials for DLL3/B7-H3. ([Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [VISION](https://onco.cc/trials/vision/), [Cabazitaxel](https://onco.cc/drugs/cabazitaxel/), [Radium-223 dichloride](https://onco.cc/drugs/radium-223/), [ALSYMPCA](https://onco.cc/trials/alsympca/), [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://onco.cc/trials/alphabreak/), [Xaluritamig](https://onco.cc/drugs/xaluritamig/), [XALute](https://onco.cc/trials/xalute/), [Pasritamig](https://onco.cc/drugs/pasritamig/), [Mevrometostat](https://onco.cc/drugs/mevrometostat/), [MEVPRO-1](https://onco.cc/trials/mevpro-1/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/))

## State of the art

- Theranostic pairing of PSMA PET and Pluvicto.
- Genotype-directed doublets.
- AI pathology guiding ADT duration.
- Radioligand therapy across the metastatic continuum: 177Lu-PSMA-617 approved post-taxane (2022), pre-taxane (2025), and at first metastatic diagnosis with ARPI (31 July 2026).
- Triplet therapy (ADT + ARPI + docetaxel) for high-volume de novo disease, with OS HR ~0.7 (ARASENS, PEACE-1).
- Genotype-directed doublets: PARP inhibitor + ARPI for HRR-mutant (OS benefit in TALAPRO-2) and capivasertib + abiraterone for PTEN-deficient disease (2026).
- Diagnostic pathway rebuilt around MRI-first biopsy and PSMA PET staging; active surveillance is default for low-risk disease.
- AI pathology (ArteraAI Prostate) is FDA-authorised to predict who benefits from adding hormone therapy to radiation.
- First immunotherapies with real activity: STEAP1 and KLK2 T-cell engagers in phase 3, after checkpoint inhibitors failed in unselected disease.

## Open problems

- Overdiagnosis vs. underdiagnosis in screening.
- Neuroendocrine transformation.
- Ac-225 supply.
- Screening trade-off: PSA reduces mortality by ~20% but overdiagnoses; MRI-first and risk-adapted intervals are only partly adopted.
- Neuroendocrine / lineage-plastic transformation in ~15-20% of late mCRPC has no targeted therapy; DLL3 and B7-H3 agents are being borrowed from SCLC.
- AR-V7 and N-terminal-domain resistance: masofaniten failed; AR degraders remain preclinical/early.
- Radioligand sequencing and resistance: 10% PSMA-negative disease, heterogeneity, and no proven therapy after 177Lu failure outside trials; Ac-225 supply is the constraint.
- Overall survival has been hard to show for PSMA radioligands beyond VISION (SPLASH, PSMAfore, TheraP confounded by crossover).
- Immunotherapy: checkpoint inhibitors fail in unselected disease; engagers bring cytokine release and need outpatient models.
- Equity: Black men have ~70% higher incidence and double the mortality yet are under-enrolled in trials; earlier, risk-adapted screening is the lever.
- Bone health, cardiovascular risk, and cognitive effects of long-term ADT in men living a decade or more.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer

## Connected records

- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)
- pairings: [AI pathology → androgen deprivation duration](https://onco.cc/pairings/ai-pathology-to-adt/), [Beta radioligand → alpha radioligand](https://onco.cc/pairings/beta-then-alpha/), [Caution: proton therapy vs IMRT](https://onco.cc/pairings/proton-vs-imrt/), [PARP inhibitor + AR pathway inhibitor (prostate)](https://onco.cc/pairings/parp-plus-arpi/), [PSMA PET → PSMA radioligand therapy](https://onco.cc/pairings/psma-pet-to-rlt/)
- collections: [NHS Jewish BRCA Testing Programme](https://onco.cc/collections/nhs-jewish-brca-testing/), [PROMISE registry: free germline testing in prostate cancer](https://onco.cc/collections/prostate-cancer-promise/), [Prostate Cancer Foundation (PCF)](https://onco.cc/collections/prostate-cancer-foundation/), [UroToday](https://onco.cc/collections/src-urotoday/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://onco.cc/technologies/actinium-225-supply/), [Active surveillance](https://onco.cc/technologies/active-surveillance/), [Adaptive therapy (evolution-based dosing)](https://onco.cc/technologies/adaptive-therapy-dynamics/), [AI scoring of biomarkers and grade on pathology slides](https://onco.cc/technologies/ai-pathology-scoring/), [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [Aspirin for cancer prevention and adjuvant therapy](https://onco.cc/technologies/aspirin-cancer-prevention/), [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [Biology-guided radiotherapy (RefleXion X1, SCINTIX)](https://onco.cc/technologies/biology-guided-radiotherapy/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [C-arm medical linear accelerators (TrueBeam, Versa HD and others)](https://onco.cc/technologies/c-arm-linac/), [Cancer neuroscience: cutting the nerve supply](https://onco.cc/technologies/nerve-tumour-denervation/), [Carbon-ion synchrotrons and facilities](https://onco.cc/technologies/carbon-ion-synchrotrons/), [CellSearch circulating tumour cell count](https://onco.cc/technologies/cellsearch-ctc-count/), [Circulating tumour cell capture](https://onco.cc/technologies/ctc-capture/), [Cryoablation systems](https://onco.cc/technologies/cryoablation-systems/), [CyberKnife robotic radiosurgery](https://onco.cc/technologies/cyberknife/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Dendritic cell vaccines](https://onco.cc/technologies/dendritic-cell-vaccines/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Elastography and contrast-enhanced ultrasound](https://onco.cc/technologies/ultrasound-elastography-ceus/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [Focused ultrasound & histotripsy](https://onco.cc/technologies/hifu-histotripsy/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Gamma probes, handheld gamma cameras and dose calibrators](https://onco.cc/technologies/gamma-probes-dose-calibrators/), [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/), [Genetically engineered mouse models](https://onco.cc/technologies/genetically-engineered-mouse-models/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [High-dose-rate brachytherapy](https://onco.cc/technologies/hdr-brachytherapy/), [HRD genomic scar scores (GIS, LOH, HRDetect)](https://onco.cc/technologies/hrd-genomic-scar-scores/), [Hyperbaric oxygen for late radiation injury](https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)](https://onco.cc/technologies/in-room-imaging-systems/), [Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)](https://onco.cc/technologies/intraoperative-fluorescence-imaging-systems/), [Irreversible electroporation (NanoKnife)](https://onco.cc/technologies/irreversible-electroporation/), [Low-dose-rate seed brachytherapy](https://onco.cc/technologies/ldr-seed-brachytherapy/), [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/), [Magnetic nanoparticle hyperthermia](https://onco.cc/technologies/magnetic-nanoparticle-hyperthermia/), [Mediterranean and plant-forward dietary patterns](https://onco.cc/technologies/mediterranean-plant-forward-diet/), [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/), [MRI](https://onco.cc/technologies/mri/), [MRI field strengths: 1.5 T, 3 T and 7 T](https://onco.cc/technologies/mri-field-strengths/), [Multiparametric prostate MRI (PI-RADS)](https://onco.cc/technologies/mp-mri/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Oncology information and record-and-verify systems (ARIA, MOSAIQ)](https://onco.cc/technologies/oncology-information-systems/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Parsortix label-free circulating tumour cell harvest](https://onco.cc/technologies/parsortix-ctc-harvest/), [Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)](https://onco.cc/technologies/patient-positioning-surface-guidance-systems/), [Photodynamic therapy lasers and light sources](https://onco.cc/technologies/photodynamic-therapy-lasers/), [Photothermal (plasmonic) nanoparticle ablation](https://onco.cc/technologies/photothermal-nanoparticles/), [Polygenic risk scores for cancer](https://onco.cc/technologies/polygenic-risk-scores/), [Probiotics for chemotherapy and radiotherapy diarrhoea](https://onco.cc/technologies/probiotics-treatment-diarrhoea/), [Proton therapy machines: cyclotrons, synchrotrons and single-room systems](https://onco.cc/technologies/proton-therapy-systems/), [PSA and MRI-first prostate cancer screening](https://onco.cc/technologies/prostate-screening-psa-mri/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://onco.cc/technologies/quantitative-imaging-biomarkers/), [RAD51 foci assay (functional HRD test)](https://onco.cc/technologies/rad51-foci-assay/), [Radioligand plus DNA-repair inhibitor combinations](https://onco.cc/technologies/radionuclide-parp-combination/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://onco.cc/technologies/radiopharmaceutical-gmp-release/), [Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)](https://onco.cc/technologies/radiotherapy-qa-phantoms-dosimeters/), [Red and processed meat reduction](https://onco.cc/technologies/red-processed-meat-reduction/), [Remote afterloaders for HDR brachytherapy](https://onco.cc/technologies/brachytherapy-afterloaders/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://onco.cc/technologies/research-reactor-isotope-production/), [Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)](https://onco.cc/technologies/respiratory-gating-tumour-tracking-systems/), [Ring-gantry linacs (Halcyon, Ethos)](https://onco.cc/technologies/ring-gantry-linac/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Soy foods and breast cancer](https://onco.cc/technologies/soy-breast-cancer/), [SPECT/CT](https://onco.cc/technologies/spect-ct/), [Stereotactic ablative radiotherapy for oligometastatic disease](https://onco.cc/technologies/sabr-oligometastases/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/), [Surgical robots: da Vinci, Hugo, Versius and single-port systems](https://onco.cc/technologies/surgical-robot-platforms/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/), [Time-restricted eating in cancer prevention and survivorship](https://onco.cc/technologies/time-restricted-eating/), [TomoTherapy and Radixact (helical radiotherapy)](https://onco.cc/technologies/tomotherapy/), [Vitamin D and omega-3 supplementation](https://onco.cc/technologies/vitamin-d-omega3-supplementation/), [Whole-body MRI](https://onco.cc/technologies/whole-body-mri/)
- targets: [5-alpha-reductase type 2 (SRD5A2)](https://onco.cc/targets/srd5a2/), [ACVR2A](https://onco.cc/targets/acvr2a/), [ADRA1A](https://onco.cc/targets/adra1a/), [AKT](https://onco.cc/targets/akt/), [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [ANK1](https://onco.cc/targets/ank1/), [ANO7](https://onco.cc/targets/ano7/), [APC](https://onco.cc/targets/apc/), [ATM](https://onco.cc/targets/atm/), [B7-H3](https://onco.cc/targets/b7h3/), [BARD1](https://onco.cc/targets/bard1/), [BCLAF1](https://onco.cc/targets/bclaf1/), [BIK](https://onco.cc/targets/bik/), [BMP6](https://onco.cc/targets/bmp6/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [BRD4](https://onco.cc/targets/brd4/), [BRIP1](https://onco.cc/targets/brip1/), [C11orf65](https://onco.cc/targets/c11orf65/), [CAMTA1](https://onco.cc/targets/camta1/), [CASZ1](https://onco.cc/targets/casz1/), [CD28](https://onco.cc/targets/cd28/), [CD44](https://onco.cc/targets/cd44/), [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/), [CDCA7](https://onco.cc/targets/cdca7/), [CDH1](https://onco.cc/targets/cdh1/), [CDK12](https://onco.cc/targets/cdk12/), [CDKN1B](https://onco.cc/targets/cdkn1b/), [CFLAR](https://onco.cc/targets/cflar/), [CHEK1](https://onco.cc/targets/chek1/), [CHEK2](https://onco.cc/targets/chek2/), [CLTCL1](https://onco.cc/targets/cltcl1/), [CNOT3](https://onco.cc/targets/cnot3/), [CSMD3](https://onco.cc/targets/csmd3/), [CTNNA2](https://onco.cc/targets/ctnna2/), [CTNNB1](https://onco.cc/targets/ctnnb1/), [CYLD](https://onco.cc/targets/cyld/), [CYP11A1 (cholesterol side-chain cleavage enzyme)](https://onco.cc/targets/cyp11a1/), [CYP17A1 (17-alpha-hydroxylase/17,20-lyase)](https://onco.cc/targets/cyp17a1/), [DCAF12L2](https://onco.cc/targets/dcaf12l2/), [DCC](https://onco.cc/targets/dcc/), [DEFA1](https://onco.cc/targets/defa1/), [DLL3](https://onco.cc/targets/dll3/), [EDNRA](https://onco.cc/targets/ednra/), [EHBP1](https://onco.cc/targets/ehbp1/), [EIF1AX](https://onco.cc/targets/eif1ax/), [ELAC2](https://onco.cc/targets/elac2/), [EPHA3](https://onco.cc/targets/epha3/), [EPHB2](https://onco.cc/targets/ephb2/), [EPS15](https://onco.cc/targets/eps15/), [ERG](https://onco.cc/targets/erg/), [ESR2](https://onco.cc/targets/esr2/), [ETV1](https://onco.cc/targets/etv1/), [ETV4](https://onco.cc/targets/etv4/), [EZH2](https://onco.cc/targets/ezh2/), [FAM174B](https://onco.cc/targets/fam174b/), [FANCA](https://onco.cc/targets/fanca/), [FANCL](https://onco.cc/targets/fancl/), [FAT3](https://onco.cc/targets/fat3/), [FAT4](https://onco.cc/targets/fat4/), [FBLN2](https://onco.cc/targets/fbln2/), [FBXO11](https://onco.cc/targets/fbxo11/), [FDPS](https://onco.cc/targets/fdps/), [FGD1](https://onco.cc/targets/fgd1/), [FGF13](https://onco.cc/targets/fgf13/), [FOXA1](https://onco.cc/targets/foxa1/), [FOXP1](https://onco.cc/targets/foxp1/), [GAS6](https://onco.cc/targets/gas6/), [GATA2](https://onco.cc/targets/gata2/), [GnRH receptor (GNRHR)](https://onco.cc/targets/gnrhr/), [GRIN2A](https://onco.cc/targets/grin2a/), [GRPR (gastrin-releasing peptide receptor)](https://onco.cc/targets/grpr/), [HOXB13](https://onco.cc/targets/hoxb13/), [HRAS](https://onco.cc/targets/hras/), [IGF2](https://onco.cc/targets/igf2/), [IL6ST](https://onco.cc/targets/il6st/), [INHBB](https://onco.cc/targets/inhbb/), [IRS2](https://onco.cc/targets/irs2/), [IRX4](https://onco.cc/targets/irx4/), [ITGA6](https://onco.cc/targets/itga6/), [JAZF1](https://onco.cc/targets/jazf1/), [KAT6B](https://onco.cc/targets/kat6b/), [KDM5D](https://onco.cc/targets/kdm5d/), [KDM6A](https://onco.cc/targets/kdm6a/), [KLF4](https://onco.cc/targets/klf4/), [KLF6](https://onco.cc/targets/klf6/), [KLK2 (kallikrein-2)](https://onco.cc/targets/klk2/), [KLK3](https://onco.cc/targets/klk3/), [KMT2C](https://onco.cc/targets/kmt2c/), [KMT2D](https://onco.cc/targets/kmt2d/), [KRT18](https://onco.cc/targets/krt18/), [LIV-1 (SLC39A6)](https://onco.cc/targets/liv1/), [LRP1B](https://onco.cc/targets/lrp1b/), [LZTR1](https://onco.cc/targets/lztr1/), [MDM4](https://onco.cc/targets/mdm4/), [MECOM](https://onco.cc/targets/mecom/), [MED12](https://onco.cc/targets/med12/), [MGA](https://onco.cc/targets/mga/), [MIEN1](https://onco.cc/targets/mien1/), [MITF](https://onco.cc/targets/mitf/), [MRE11](https://onco.cc/targets/mre11/), [MSH6](https://onco.cc/targets/msh6/), [MSMB](https://onco.cc/targets/msmb/), [MTHFR](https://onco.cc/targets/mthfr/), [MXI1](https://onco.cc/targets/mxi1/), [MYC](https://onco.cc/targets/myc-gene/), [MYEOV](https://onco.cc/targets/myeov/), [MYH11](https://onco.cc/targets/myh11/), [NBN](https://onco.cc/targets/nbn/), [NCOA2](https://onco.cc/targets/ncoa2/), [NCOR1](https://onco.cc/targets/ncor1/), [NCOR2](https://onco.cc/targets/ncor2/), [NKX3-1](https://onco.cc/targets/nkx3-1/), [NOTCH2](https://onco.cc/targets/notch2/), [OTX1](https://onco.cc/targets/otx1/), [PALB2](https://onco.cc/targets/palb2/), [PARP](https://onco.cc/targets/parp/), [PARP2](https://onco.cc/targets/parp2/), [PARP3](https://onco.cc/targets/parp3/), [PAX5](https://onco.cc/targets/pax5/), [PDLIM5](https://onco.cc/targets/pdlim5/), [PIK3CB](https://onco.cc/targets/pik3cb/), [POGLUT3](https://onco.cc/targets/poglut3/), [POLK](https://onco.cc/targets/polk/), [POU5F1B](https://onco.cc/targets/pou5f1b/), [PPP1R14A](https://onco.cc/targets/ppp1r14a/), [PPP2R2A](https://onco.cc/targets/ppp2r2a/), [PRDM1](https://onco.cc/targets/prdm1/), [PRKCB](https://onco.cc/targets/prkcb/), [PRKD1](https://onco.cc/targets/prkd1/), [Prostatic acid phosphatase (ACP3, PAP)](https://onco.cc/targets/pap/), [PSMA](https://onco.cc/targets/psma/), [PTK6 (BRK)](https://onco.cc/targets/ptk6/), [RAD50](https://onco.cc/targets/rad50/), [RAD51B](https://onco.cc/targets/rad51b/), [RAD51C](https://onco.cc/targets/rad51c/), [RAD51D](https://onco.cc/targets/rad51d/), [RAD54L](https://onco.cc/targets/rad54l/), [RANK ligand (RANKL)](https://onco.cc/targets/rankl/), [RASSF6](https://onco.cc/targets/rassf6/), [RBFOX1](https://onco.cc/targets/rbfox1/), [RFX7](https://onco.cc/targets/rfx7/), [RGS17](https://onco.cc/targets/rgs17/), [RHOA](https://onco.cc/targets/rhoa/), [RNASEL](https://onco.cc/targets/rnasel/), [RNF213](https://onco.cc/targets/rnf213/), [RNF43](https://onco.cc/targets/rnf43/), [ROBO2](https://onco.cc/targets/robo2/), [RSPO2](https://onco.cc/targets/rspo2/), [RUNX1T1](https://onco.cc/targets/runx1t1/), [SETD2](https://onco.cc/targets/setd2/), [SIM2](https://onco.cc/targets/sim2/), [SKIL](https://onco.cc/targets/skil/), [SLC22A3](https://onco.cc/targets/slc22a3/), [SMAD4](https://onco.cc/targets/smad4/), [SOX21](https://onco.cc/targets/sox21/), [SPDL1](https://onco.cc/targets/spdl1/), [SPEN](https://onco.cc/targets/spen/), [SPOP](https://onco.cc/targets/spop/), [SRD5A1](https://onco.cc/targets/srd5a1/), [SRD5A3](https://onco.cc/targets/srd5a3/), [STEAP1](https://onco.cc/targets/steap1/), [STK11](https://onco.cc/targets/stk11/), [SUZ12](https://onco.cc/targets/suz12/), [TBX3](https://onco.cc/targets/tbx3/), [TCF7L2](https://onco.cc/targets/tcf7l2/), [TERT](https://onco.cc/targets/tert/), [TFRC](https://onco.cc/targets/tfrc/), [TGFBR3](https://onco.cc/targets/tgfbr3/), [TMEM17](https://onco.cc/targets/tmem17/), [TMPRSS2](https://onco.cc/targets/tmprss2/), [TNS3](https://onco.cc/targets/tns3/), [TRIM24](https://onco.cc/targets/trim24/), [TSPYL1](https://onco.cc/targets/tspyl1/), [TUBA1A](https://onco.cc/targets/tuba1a/), [TUBA1B](https://onco.cc/targets/tuba1b/), [TUBA1C](https://onco.cc/targets/tuba1c/), [TUBA3C](https://onco.cc/targets/tuba3c/), [TUBA3E](https://onco.cc/targets/tuba3e/), [TUBA4A](https://onco.cc/targets/tuba4a/), [TUBB1](https://onco.cc/targets/tubb1/), [TUBB2A](https://onco.cc/targets/tubb2a/), [TUBB2B](https://onco.cc/targets/tubb2b/), [TUBB3](https://onco.cc/targets/tubb3/), [TUBB4A](https://onco.cc/targets/tubb4a/), [TUBB4B](https://onco.cc/targets/tubb4b/), [TUBB6](https://onco.cc/targets/tubb6/), [TUBB8](https://onco.cc/targets/tubb8/), [U2AF1](https://onco.cc/targets/u2af1/), [USP28](https://onco.cc/targets/usp28/), [USP6](https://onco.cc/targets/usp6/), [USP9X](https://onco.cc/targets/usp9x/), [VISTA](https://onco.cc/targets/vista/), [VPS53](https://onco.cc/targets/vps53/), [XPC](https://onco.cc/targets/xpc/), [ZBTB16](https://onco.cc/targets/zbtb16/), [ZFHX3](https://onco.cc/targets/zfhx3/), [ZMIZ1](https://onco.cc/targets/zmiz1/), [ZMYM2](https://onco.cc/targets/zmym2/), [ZMYM3](https://onco.cc/targets/zmym3/), [ZNF429](https://onco.cc/targets/znf429/)
- drugs: [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/), [AAA817](https://onco.cc/drugs/aaa817/), [Abarelix](https://onco.cc/drugs/abarelix/), [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/), [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/), [Aminoglutethimide](https://onco.cc/drugs/aminoglutethimide/), [AMO959](https://onco.cc/drugs/amo959/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [ArteraAI Prostate](https://onco.cc/drugs/artera-ai-prostate/), [AZD6621](https://onco.cc/drugs/azd6621/), [AZD9750](https://onco.cc/drugs/azd9750/), [Bicalutamide](https://onco.cc/drugs/bicalutamide/), [BMS-986365](https://onco.cc/drugs/bms-986365/), [BNT324](https://onco.cc/drugs/bnt324/), [BRACAnalysis CDx](https://onco.cc/drugs/bracanalysis-cdx/), [Buserelin](https://onco.cc/drugs/buserelin/), [Cabazitaxel](https://onco.cc/drugs/cabazitaxel/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Choline C-11](https://onco.cc/drugs/choline-c11/), [Darolutamide](https://onco.cc/drugs/darolutamide/), [Decipher Prostate](https://onco.cc/drugs/decipher-prostate/), [Degarelix](https://onco.cc/drugs/degarelix/), [Denosumab](https://onco.cc/drugs/denosumab/), [Diethylstilbestrol](https://onco.cc/drugs/diethylstilbestrol/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Estramustine](https://onco.cc/drugs/estramustine/), [Florastamin F-18](https://onco.cc/drugs/florastamin-f18/), [Flotufolastat F-18](https://onco.cc/drugs/flotufolastat/), [Fluciclovine F-18](https://onco.cc/drugs/fluciclovine-f18/), [Flutamide](https://onco.cc/drugs/flutamide/), [FPI-2265](https://onco.cc/drugs/fpi-2265/), [Gallium-68 gozetotide (PSMA-11)](https://onco.cc/drugs/ga68-psma-11/), [Gotistobart](https://onco.cc/drugs/gotistobart/), [Histrelin](https://onco.cc/drugs/histrelin/), [HRS-4357](https://onco.cc/drugs/hrs-4357/), [HS-20093](https://onco.cc/drugs/hs-20093/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/), [Illuccix (kit for Ga-68 gozetotide)](https://onco.cc/drugs/illuccix/), [JNJ-87189401](https://onco.cc/drugs/jnj-87189401/), [Leuprolide (leuprorelin) and GnRH agonists](https://onco.cc/drugs/leuprolide/), [Locametz (kit for Ga-68 gozetotide)](https://onco.cc/drugs/locametz/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/), [Masofaniten](https://onco.cc/drugs/masofaniten/), [Mevrometostat](https://onco.cc/drugs/mevrometostat/), [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/), [Nilutamide](https://onco.cc/drugs/nilutamide/), [Niraparib](https://onco.cc/drugs/niraparib/), [NUV-1511](https://onco.cc/drugs/nuv-1511/), [Olaparib](https://onco.cc/drugs/olaparib/), [Oncotype DX Genomic Prostate Score](https://onco.cc/drugs/oncotype-dx-gps/), [Opevesostat](https://onco.cc/drugs/opevesostat/), [Padeliporfin](https://onco.cc/drugs/padeliporfin/), [Paige Prostate Detect](https://onco.cc/drugs/paige-prostate/), [Pasritamig](https://onco.cc/drugs/pasritamig/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [PF-07248144](https://onco.cc/drugs/pf-07248144/), [Piflufolastat F-18 / Pylarify TruVu](https://onco.cc/drugs/pylarify/), [Prednisone](https://onco.cc/drugs/prednisone/), [Prolaris](https://onco.cc/drugs/prolaris/), [PSMA-1007 F-18](https://onco.cc/drugs/psma-1007-f18/), [QLC5508](https://onco.cc/drugs/qlc5508/), [QLH12016](https://onco.cc/drugs/qlh12016/), [Radium-223 dichloride](https://onco.cc/drugs/radium-223/), [Relugolix](https://onco.cc/drugs/relugolix/), [Rezvilutamide](https://onco.cc/drugs/rezvilutamide/), [Rinzimetostat](https://onco.cc/drugs/rinzimetostat/), [Rucaparib](https://onco.cc/drugs/rucaparib/), [RV001V](https://onco.cc/drugs/rv001v/), [Samarium-153 lexidronam](https://onco.cc/drugs/samarium-153-lexidronam/), [Saruparib](https://onco.cc/drugs/saruparib/), [Sipuleucel-T](https://onco.cc/drugs/sipuleucel-t/), [Talazoparib](https://onco.cc/drugs/talazoparib/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/), [Triptorelin](https://onco.cc/drugs/triptorelin/), [VB15010](https://onco.cc/drugs/vb15010/), [Vudalimab](https://onco.cc/drugs/vudalimab/), [Xaluritamig](https://onco.cc/drugs/xaluritamig/), [XNW5004](https://onco.cc/drugs/xnw5004/), [YL201](https://onco.cc/drugs/yl201/), [ZEN-3694](https://onco.cc/drugs/zen-3694/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)
- companies: [AB Science](https://onco.cc/companies/ab-science/), [ABX advanced biochemical compounds](https://onco.cc/companies/abx-advanced-biochemical-compounds/), [Achieve Life Sciences (formerly OncoGenex)](https://onco.cc/companies/achieve-life-sciences/), [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/), [Active Biotech](https://onco.cc/companies/active-biotech/), [Adialante](https://onco.cc/companies/adialante/), [Adicet Bio](https://onco.cc/companies/adicet-bio/), [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/), [Aktis Oncology](https://onco.cc/companies/aktis-oncology/), [Alpha Tau Medical](https://onco.cc/companies/alpha-tau-medical/), [Amgen](https://onco.cc/companies/amgen/), [AngioDynamics](https://onco.cc/companies/angiodynamics/), [ANGLE plc](https://onco.cc/companies/angle-plc/), [ANZUP Cancer Trials Group](https://onco.cc/companies/anzup/), [ARTBIO](https://onco.cc/companies/artbio/), [Artera](https://onco.cc/companies/artera/), [Astellas](https://onco.cc/companies/astellas/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Bavarian Nordic](https://onco.cc/companies/bavarian-nordic/), [Bayer](https://onco.cc/companies/bayer/), [Blue Earth Diagnostics (Bracco)](https://onco.cc/companies/blue-earth-diagnostics/), [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/), [Clarity Pharmaceuticals](https://onco.cc/companies/clarity-pharmaceuticals/), [Clovis Oncology](https://onco.cc/companies/clovis-oncology/), [CMR Surgical](https://onco.cc/companies/cmr-surgical/), [Convergent Therapeutics](https://onco.cc/companies/convergent-therapeutics/), [Curium](https://onco.cc/companies/curium/), [Dendreon](https://onco.cc/companies/dendreon/), [Endo (now Keenova Therapeutics and Par Health)](https://onco.cc/companies/endo/), [ESSA Pharma](https://onco.cc/companies/essa-pharma/), [Eurofarma](https://onco.cc/companies/eurofarma/), [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/), [Foghorn Therapeutics](https://onco.cc/companies/foghorn-therapeutics/), [Foresee Pharmaceuticals](https://onco.cc/companies/foresee-pharmaceuticals/), [FutureChem](https://onco.cc/companies/futurechem/), [GTx](https://onco.cc/companies/gtx/), [Halda Therapeutics](https://onco.cc/companies/halda-therapeutics/), [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/), [Ibex Medical Analytics](https://onco.cc/companies/ibex-medical-analytics/), [intoDNA](https://onco.cc/companies/intodna/), [Ionis Pharmaceuticals](https://onco.cc/companies/ionis/), [Janux Therapeutics](https://onco.cc/companies/janux-therapeutics/), [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [K36 Therapeutics](https://onco.cc/companies/k36-therapeutics/), [Lantheus](https://onco.cc/companies/lantheus/), [Lightpoint Medical](https://onco.cc/companies/lightpoint-medical/), [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/), [MDxHealth](https://onco.cc/companies/mdxhealth/), [Menarini Silicon Biosystems](https://onco.cc/companies/menarini-silicon-biosystems/), [Minghui Pharmaceutical](https://onco.cc/companies/minghui-pharmaceutical/), [Monte Rosa Therapeutics](https://onco.cc/companies/monte-rosa/), [MRC Clinical Trials Unit at UCL](https://onco.cc/companies/mrc-ctu/), [Myriad Genetics](https://onco.cc/companies/myriad-genetics/), [Norroy Bioscience](https://onco.cc/companies/norroy-bioscience/), [Novartis](https://onco.cc/companies/novartis/), [NRG Oncology](https://onco.cc/companies/nrg-oncology/), [Nuvation Bio](https://onco.cc/companies/nuvation-bio/), [Oakwood Laboratories](https://onco.cc/companies/oakwood-laboratories/), [OncoC4](https://onco.cc/companies/oncoc4/), [ORIC Pharmaceuticals](https://onco.cc/companies/oric-pharmaceuticals/), [Orion, Orion Pharma](https://onco.cc/companies/orion-orion-pharma/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [pharma&](https://onco.cc/companies/pharmaand/), [POINT Biopharma](https://onco.cc/companies/point-biopharma/), [Profound Medical](https://onco.cc/companies/profound-medical/), [Proxygen](https://onco.cc/companies/proxygen/), [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/), [Radiopharm Theranostics](https://onco.cc/companies/radiopharm-theranostics/), [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/), [Sorrento Therapeutics](https://onco.cc/companies/sorrento-therapeutics/), [SOTIO Biotech](https://onco.cc/companies/sotio/), [SpectraCure](https://onco.cc/companies/spectracure/), [Sumitomo Pharma (Myovant)](https://onco.cc/companies/sumitomo-pharma/), [Telix Pharmaceuticals](https://onco.cc/companies/telix/), [Tolmar](https://onco.cc/companies/tolmar/), [TROG Cancer Research](https://onco.cc/companies/trog/), [Valar Labs](https://onco.cc/companies/valar-labs/), [Veracyte (Decipher)](https://onco.cc/companies/veracyte/), [Verity Pharmaceuticals](https://onco.cc/companies/verity-pharma/), [Veru](https://onco.cc/companies/veru/), [ViewRay (MRIdian)](https://onco.cc/companies/viewray/), [X-Zell](https://onco.cc/companies/x-zell/)
- institutions: [Aarhus University Hospital](https://onco.cc/institutions/aarhus-university-hospital/), [All India Institute of Medical Sciences, New Delhi](https://onco.cc/institutions/aiims-delhi/), [Apollo Hospitals (Apollo Cancer Centres)](https://onco.cc/institutions/apollo-hospitals/), [Barts Cancer Institute / Barts Health NHS Trust](https://onco.cc/institutions/barts-cancer-institute/), [Centre hospitalier de l'Université de Montréal (CHUM)](https://onco.cc/institutions/chum/), [Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand](https://onco.cc/institutions/wits-charlotte-maxeke/), [Chinese PLA General Hospital](https://onco.cc/institutions/pla-general-hospital/), [CHU de Québec - Université Laval](https://onco.cc/institutions/chu-de-quebec/), [Chulabhorn Hospital / Chulabhorn Royal Academy](https://onco.cc/institutions/chulabhorn-hospital/), [Cleveland Clinic Abu Dhabi](https://onco.cc/institutions/cleveland-clinic-abu-dhabi/), [Comprehensive Cancer Center Freiburg (CCCF)](https://onco.cc/institutions/ccc-freiburg/), [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/), [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/), [Fox Chase Cancer Center](https://onco.cc/institutions/fox-chase/), [Fundación Arturo López Pérez](https://onco.cc/institutions/falp-chile/), [Garvan Institute of Medical Research / Kinghorn Cancer Centre](https://onco.cc/institutions/garvan-institute/), [Ghent University Hospital / Cancer Research Institute Ghent](https://onco.cc/institutions/uz-gent/), [Gunma University Heavy Ion Medical Center](https://onco.cc/institutions/gunma-heavy-ion-medical-center/), [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/), [Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre](https://onco.cc/institutions/guys-st-thomas/), [Herbert Irving Comprehensive Cancer Center, Columbia University](https://onco.cc/institutions/columbia-hicc/), [Hokkaido University Hospital](https://onco.cc/institutions/hokkaido-university-hospital/), [Hospital de Clínicas de Porto Alegre](https://onco.cc/institutions/hcpa-porto-alegre/), [Huntsman Cancer Institute, University of Utah](https://onco.cc/institutions/huntsman/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://onco.cc/institutions/inselspital-bern/), [Instituto Nacional de Câncer (INCA)](https://onco.cc/institutions/inca-brazil/), [Instituto Português de Oncologia do Porto Francisco Gentil](https://onco.cc/institutions/ipo-porto/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://onco.cc/institutions/irst-meldola/), [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/), [Kenyatta National Hospital](https://onco.cc/institutions/kenyatta-national-hospital/), [Korle Bu Teaching Hospital](https://onco.cc/institutions/korle-bu-teaching-hospital/), [Lagos University Teaching Hospital](https://onco.cc/institutions/luth-lagos/), [Masaryk Memorial Cancer Institute](https://onco.cc/institutions/mou-brno/), [Movember](https://onco.cc/institutions/movember/), [Northern Ireland Cancer Centre, Belfast City Hospital](https://onco.cc/institutions/northern-ireland-cancer-centre/), [Oncology Institute of Southern Switzerland (IOSI)](https://onco.cc/institutions/iosi-bellinzona/), [Oslo University Hospital, The Norwegian Radium Hospital](https://onco.cc/institutions/oslo-radium-hospital/), [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/), [Postgraduate Institute of Medical Education and Research, Chandigarh](https://onco.cc/institutions/pgimer-chandigarh/), [Prostate Cancer Foundation](https://onco.cc/institutions/pcf/), [QST Hospital (National Institutes for Quantum Science and Technology)](https://onco.cc/institutions/qst-hospital/), [Radboudumc Centre for Oncology](https://onco.cc/institutions/radboudumc/), [Robert H. Lurie Comprehensive Cancer Center of Northwestern University](https://onco.cc/institutions/northwestern-lurie/), [Royal Adelaide Hospital](https://onco.cc/institutions/royal-adelaide-hospital/), [Sidney Kimmel Comprehensive Cancer Center at Jefferson Health](https://onco.cc/institutions/jefferson-kimmel/), [Skåne University Hospital / Lund University Cancer Centre](https://onco.cc/institutions/lund-skane/), [South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide](https://onco.cc/institutions/saigenci-adelaide/), [Stand Up To Cancer](https://onco.cc/institutions/stand-up-to-cancer/), [Sunnybrook Odette Cancer Centre](https://onco.cc/institutions/sunnybrook-odette/), [Tays Cancer Centre, Tampere University Hospital](https://onco.cc/institutions/tays-cancer-centre/), [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/), [TUM Klinikum rechts der Isar / CCC München](https://onco.cc/institutions/tum-munich/), [UC Davis Comprehensive Cancer Center](https://onco.cc/institutions/uc-davis-cancer/), [UCLA Jonsson Comprehensive Cancer Center](https://onco.cc/institutions/ucla-jonsson/), [UMC Utrecht Cancer Center](https://onco.cc/institutions/umc-utrecht/), [Universitätsklinikum Hamburg-Eppendorf](https://onco.cc/institutions/uke-hamburg/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/), [University Hospital Düsseldorf / CIO Düsseldorf](https://onco.cc/institutions/uk-duesseldorf/), [University of Chicago Medicine Comprehensive Cancer Center](https://onco.cc/institutions/uchicago-cancer/), [University of Florida Health Cancer Center](https://onco.cc/institutions/uf-health-cancer-center/), [University of Michigan Rogel Cancer Center](https://onco.cc/institutions/michigan-rogel/), [University of Wisconsin Carbone Cancer Center](https://onco.cc/institutions/uw-carbone/), [Uppsala University Hospital / Uppsala University](https://onco.cc/institutions/uppsala-akademiska/), [Vejle Hospital Cancer Centre (Lillebaelt Hospital)](https://onco.cc/institutions/vejle-cancer-centre/), [Velindre Cancer Centre](https://onco.cc/institutions/velindre-cardiff/), [West German Cancer Center (WTZ), University Hospital Essen](https://onco.cc/institutions/essen-wtz/)
- pathways: [Androgen receptor signalling](https://onco.cc/pathways/ar-signaling/), [Base excision repair, PARP & alkylation damage](https://onco.cc/pathways/base-excision-repair-parp/), [Cancer neuroscience (nerve-tumour signalling)](https://onco.cc/pathways/cancer-neuroscience/), [DNA damage response & homologous recombination](https://onco.cc/pathways/ddr/), [Double-strand break repair: HR versus end joining](https://onco.cc/pathways/homologous-recombination-repair/), [Lineage plasticity & neuroendocrine transformation](https://onco.cc/pathways/lineage-plasticity-neuroendocrine/), [Lipid synthesis, uptake & cholesterol](https://onco.cc/pathways/lipid-metabolism-cancer/), [Organ tropism: seed and soil](https://onco.cc/pathways/organ-tropism-seed-soil/), [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [Prostate cancer (KEGG map)](https://onco.cc/pathways/prostate-cancer-signalling/), [RNA splicing](https://onco.cc/pathways/rna-splicing/), [Transcriptional machinery & addiction](https://onco.cc/pathways/transcription-addiction/), [Tumour dormancy](https://onco.cc/pathways/tumor-dormancy/), [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)
- terms: [Active surveillance and observation](https://onco.cc/terms/active-surveillance-term/), [Adenocarcinoma](https://onco.cc/terms/adenocarcinoma/), [Androgen deprivation therapy (ADT)](https://onco.cc/terms/adt/), [Androgen receptor pathway inhibitor (ARPI)](https://onco.cc/terms/arpi/), [AR-V7 splice variant](https://onco.cc/terms/ar-v7/), [Biochemical recurrence (BCR)](https://onco.cc/terms/biochemical-recurrence/), [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Brachytherapy (internal radiotherapy)](https://onco.cc/terms/brachytherapy-term/), [Cancer health disparities and equity](https://onco.cc/terms/cancer-health-disparities/), [Cancer vaccines and oncolytic viruses](https://onco.cc/terms/vaccines-and-oncolytic-viruses/), [Castration-resistant prostate cancer (CRPC)](https://onco.cc/terms/castration-resistance/), [Clonal evolution and the ecological view of cancer](https://onco.cc/terms/clonal-evolution-theory/), [Crossover in trials](https://onco.cc/terms/crossover/), [Cryoablation](https://onco.cc/terms/cryoablation/), [Differentiation](https://onco.cc/terms/differentiation/), [Fiducial markers](https://onco.cc/terms/fiducial-markers/), [Germline BRCA mutation (gBRCA)](https://onco.cc/terms/gbrca-mutation/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/), [Grade](https://onco.cc/terms/tumour-grade/), [Hormone therapy](https://onco.cc/terms/hormone-therapy/), [Hypofractionation (fewer, larger radiotherapy doses)](https://onco.cc/terms/hypofractionation/), [mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)](https://onco.cc/terms/mcrpc-mhspc/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/), [Orchiectomy](https://onco.cc/terms/orchiectomy/), [Perineural invasion (PNI)](https://onco.cc/terms/perineural-invasion/), [PSA (prostate-specific antigen)](https://onco.cc/terms/psa/), [PSA50 / PSA90 response](https://onco.cc/terms/psa50/), [Radical prostatectomy](https://onco.cc/terms/prostatectomy/), [Seed and soil hypothesis of metastasis (Paget)](https://onco.cc/terms/seed-and-soil-hypothesis/), [Theranostics](https://onco.cc/terms/theranostics/), [Tumour differentiation (well / moderately / poorly differentiated)](https://onco.cc/terms/tumour-differentiation/), [Tumour marker](https://onco.cc/terms/tumour-marker/)
- trials: [[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer](https://onco.cc/trials/nct05936658/), [153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer](https://onco.cc/trials/nct00450619/), [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://onco.cc/trials/nct07189871/), [64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)](https://onco.cc/trials/nct04868604/), [64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer](https://onco.cc/trials/nct06970847/), [A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec](https://onco.cc/trials/nct07332000/), [A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)](https://onco.cc/trials/nct06925737/), [A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)](https://onco.cc/trials/nct06863272/), [A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer](https://onco.cc/trials/nct07198633/), [A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer](https://onco.cc/trials/nct07407283/), [A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer](https://onco.cc/trials/nct07258407/), [A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct07553988/), [A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC](https://onco.cc/trials/nct07255664/), [A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver](https://onco.cc/trials/nct04691804/), [A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct04478279/), [A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy](https://onco.cc/trials/nct05547061/), [A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC](https://onco.cc/trials/nct06383052/), [A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC](https://onco.cc/trials/nct06785636/), [A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer](https://onco.cc/trials/nct07005154/), [A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA](https://onco.cc/trials/nct07226986/), [A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC](https://onco.cc/trials/nct05849298/), [A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC](https://onco.cc/trials/nct06241846/), [A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer](https://onco.cc/trials/nct00006371/), [A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct07241416/), [A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07311694/), [A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct07365995/), [A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS](https://onco.cc/trials/nct06906471/), [A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer](https://onco.cc/trials/nct05658003/), [A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer](https://onco.cc/trials/nct07567846/), [A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study](https://onco.cc/trials/nct02960022/), [A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone](https://onco.cc/trials/nct06689163/), [A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)](https://onco.cc/trials/nct05288166/), [A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer](https://onco.cc/trials/nct03706365/), [A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct04557059/), [A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC](https://onco.cc/trials/nct05884398/), [A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct01946204/), [A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC](https://onco.cc/trials/nct02489318/), [A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy](https://onco.cc/trials/nct03767244/), [A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer](https://onco.cc/trials/nct05067140/), [A Study of DM002 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06751329/), [A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab](https://onco.cc/trials/nct06782555/), [A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct06842498/), [A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer](https://onco.cc/trials/nct06990880/), [A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06172478/), [A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer](https://onco.cc/trials/nct06568094/), [A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct07047118/), [A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation](https://onco.cc/trials/nct06952803/), [A Study of MHB048C in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07192120/), [A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct03431350/), [A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)](https://onco.cc/trials/nct04497844/), [A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)](https://onco.cc/trials/nct06136650/), [A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct06395519/), [A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07225946/), [A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/mcrpc/), [A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)](https://onco.cc/trials/nct05652686/), [A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer](https://onco.cc/trials/nct07230106/), [A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06533644/), [A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC](https://onco.cc/trials/nct07259213/), [A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC](https://onco.cc/trials/nct07567521/), [A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas](https://onco.cc/trials/nct04104776/), [A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ](https://onco.cc/trials/nct07213674/), [A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies](https://onco.cc/trials/nct05032040/), [A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate](https://onco.cc/trials/nct01517802/), [A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients](https://onco.cc/trials/nct06155084/), [A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer](https://onco.cc/trials/nct05794906/), [A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct06764485/), [A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer](https://onco.cc/trials/nct06609005/), [A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)](https://onco.cc/trials/himalayas-1/), [A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.](https://onco.cc/trials/nct06629779/), [A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr](https://onco.cc/trials/nct07192614/), [A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi](https://onco.cc/trials/nct07450599/), [A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07287150/), [A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease](https://onco.cc/trials/nct02663908/), [A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).](https://onco.cc/trials/nct03851640/), [A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies](https://onco.cc/trials/nct04503265/), [A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer](https://onco.cc/trials/nct05125016/), [A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta](https://onco.cc/trials/nct03972657/), [A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs](https://onco.cc/trials/nct07336446/), [AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)](https://onco.cc/trials/nct07285694/), [Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer](https://onco.cc/trials/nct00841113/), [Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.](https://onco.cc/trials/nct05422911/), [Add-Aspirin](https://onco.cc/trials/add-aspirin/), [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://onco.cc/trials/alphabreak/), [ALSYMPCA](https://onco.cc/trials/alsympca/), [An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct02257736/), [An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo](https://onco.cc/trials/nct04076059/), [An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS](https://onco.cc/trials/nct02531516/), [An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)](https://onco.cc/trials/nct07206056/), [An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.](https://onco.cc/trials/nct05939414/), [An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc](https://onco.cc/trials/nct06991556/), [An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC](https://onco.cc/trials/nct06894511/), [Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection](https://onco.cc/trials/nct05413850/), [ARAMIS](https://onco.cc/trials/aramis/), [ARANOTE](https://onco.cc/trials/aranote/), [ARASENS](https://onco.cc/trials/arasens/), [ARCHES](https://onco.cc/trials/arches/), [Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT](https://onco.cc/trials/nct07455903/), [AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)](https://onco.cc/trials/nct07611110/), [Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer](https://onco.cc/trials/nct03444844/), [CAPItello-281](https://onco.cc/trials/capitello-281/), [CHAARTED (E3805)](https://onco.cc/trials/chaarted/), [Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00024167/), [CHHiP](https://onco.cc/trials/chhip/), [Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer](https://onco.cc/trials/nct01054079/), [Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System](https://onco.cc/trials/nct03067051/), [Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct06312670/), [Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT](https://onco.cc/trials/nct03777982/), [Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer](https://onco.cc/trials/nct06235151/), [CYTALUX™for the Intraoperative Imaging of Prostate Cancer](https://onco.cc/trials/nct06434909/), [Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer](https://onco.cc/trials/nct00316927/), [Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer](https://onco.cc/trials/nct06122584/), [Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance](https://onco.cc/trials/nct07285057/), [Early Phase Study of KESONOTIDE™in Participants With Solid Tumours](https://onco.cc/trials/nct06926075/), [ECLIPSE](https://onco.cc/trials/eclipse-psma/), [Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer](https://onco.cc/trials/nct01020448/), [Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance](https://onco.cc/trials/nct01310894/), [Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer](https://onco.cc/trials/nct01875393/), [EMBARK](https://onco.cc/trials/embark/), [ENZAMET](https://onco.cc/trials/enzamet/), [Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis](https://onco.cc/trials/nct05004285/), [Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients](https://onco.cc/trials/nct06262139/), [Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer](https://onco.cc/trials/nct02260817/), [First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer](https://onco.cc/trials/nct07529717/), [First-Time-in-Human Study of GSK5471713 in Adults With mCRPC](https://onco.cc/trials/nct07332455/), [FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer](https://onco.cc/trials/nct06636682/), [Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00002881/), [FOcal RECurrent Assessment and Salvage Treatment](https://onco.cc/trials/nct01883128/), [FOG-001 in Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05919264/), [FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct06909825/), [Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06190899/), [GÖTEBORG-2 (MRI-based prostate cancer screening)](https://onco.cc/trials/goteborg-2/), [Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer](https://onco.cc/trials/nct00003653/), [Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00004054/), [Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse](https://onco.cc/trials/nct00055731/), [Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00002633/), [HORRAD](https://onco.cc/trials/horrad/), [HYPO-RT-PC](https://onco.cc/trials/hypo-rt-pc/), [Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide](https://onco.cc/trials/nct02815033/), [Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.](https://onco.cc/trials/nct07615101/), [Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients](https://onco.cc/trials/nct00884273/), [IS-002 Phase 2 Prostate Cancer Study](https://onco.cc/trials/nct05946603/), [LATITUDE](https://onco.cc/trials/latitude/), [MAGNITUDE](https://onco.cc/trials/magnitude/), [Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T](https://onco.cc/trials/nct06134232/), [MEVPRO-1](https://onco.cc/trials/mevpro-1/), [MR Image Guided Therapy in Prostate Cancer](https://onco.cc/trials/nct01377753/), [Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer](https://onco.cc/trials/nct00833248/), [ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC](https://onco.cc/trials/nct05682443/), [Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy](https://onco.cc/trials/nct06780670/), [PACE-B](https://onco.cc/trials/pace-b/), [PARTIQoL](https://onco.cc/trials/partiqol/), [PEACE-1](https://onco.cc/trials/peace-1/), [PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence](https://onco.cc/trials/nct06617481/), [PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide](https://onco.cc/trials/nct02814968/), [Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms](https://onco.cc/trials/nct03348670/), [Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer](https://onco.cc/trials/nct06139575/), [Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors](https://onco.cc/trials/nct07145255/), [Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer](https://onco.cc/trials/nct01436968/), [Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06819215/), [Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07590934/), [Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).](https://onco.cc/trials/nct05720130/), [Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System](https://onco.cc/trials/nct06807359/), [POP-RT](https://onco.cc/trials/pop-rt/), [Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy](https://onco.cc/trials/nct06056830/), [PRECISION](https://onco.cc/trials/precision-mri/), [PROfound](https://onco.cc/trials/profound/), [PROpel](https://onco.cc/trials/propel/), [proPSMA](https://onco.cc/trials/propsma/), [PROSPER](https://onco.cc/trials/prosper/), [Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer](https://onco.cc/trials/nct00567580/), [ProtecT](https://onco.cc/trials/protect/), [Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder](https://onco.cc/trials/nct07072728/), [PSMA PET Combined With MRI for the Detection of PCa](https://onco.cc/trials/nct07052214/), [PSMA-PET to Guide Prostatectomy](https://onco.cc/trials/nct05381103/), [PSMA-PreRP](https://onco.cc/trials/psma-prerp/), [PSMAddition](https://onco.cc/trials/psmaddition/), [PSMAfore](https://onco.cc/trials/psmafore/), [Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00936390/), [Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)](https://onco.cc/trials/nct02768363/), [Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer](https://onco.cc/trials/nct04457245/), [REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ](https://onco.cc/trials/nct07594106/), [RTOG 9601](https://onco.cc/trials/rtog-9601/), [SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer](https://onco.cc/trials/sabr-comet/), [Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer](https://onco.cc/trials/nct06474806/), [Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients](https://onco.cc/trials/nct05558007/), [Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06334432/), [Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct03436485/), [Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer](https://onco.cc/trials/nct00551525/), [Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents](https://onco.cc/trials/nct06120491/), [Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain](https://onco.cc/trials/nct00082927/), [SPLASH](https://onco.cc/trials/splash/), [STAMPEDE](https://onco.cc/trials/stampede/), [Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct03678025/), [Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC](https://onco.cc/trials/nct06855277/), [Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)](https://onco.cc/trials/nct06549465/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer](https://onco.cc/trials/nct02981368/), [Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer](https://onco.cc/trials/nct03739684/), [Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer](https://onco.cc/trials/nct06754085/), [Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy](https://onco.cc/trials/nct00100243/), [Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06380660/), [Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07181161/), [Study of AZD0754 in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct06267729/), [Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct04644068/), [Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer](https://onco.cc/trials/nct05367440/), [Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC](https://onco.cc/trials/nct04446117/), [Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct05348577/), [Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)](https://onco.cc/trials/nct05489211/), [Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors](https://onco.cc/trials/nct07288359/), [Study of Histrelin Subdermal Implant in Patients With Prostate Cancer](https://onco.cc/trials/nct01394263/), [Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer](https://onco.cc/trials/nct06800313/), [Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function](https://onco.cc/trials/nct06004661/), [Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)](https://onco.cc/trials/nct06136624/), [Study of Oral MRT-2359 in Selected Cancer Patients](https://onco.cc/trials/nct05546268/), [Study of Oral MRT-2359 With Apalutamide in Prostate Cancer](https://onco.cc/trials/nct07745361/), [Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)](https://onco.cc/trials/nct02861573/), [Study of PF-07248144 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04606446/), [Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer](https://onco.cc/trials/nct04114825/), [Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer](https://onco.cc/trials/nct06228053/), [Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC](https://onco.cc/trials/nct04821622/), [Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer](https://onco.cc/trials/nct03315754/), [Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06702995/), [Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)](https://onco.cc/trials/nct05171816/), [Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer](https://onco.cc/trials/nct01697384/), [Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors](https://onco.cc/trials/nct04557449/), [Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)](https://onco.cc/trials/nct06353386/), [TALAPRO-2](https://onco.cc/trials/talapro-2/), [Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).](https://onco.cc/trials/nct05219500/), [The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)](https://onco.cc/trials/nct04585750/), [The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)](https://onco.cc/trials/nct06520345/), [TheraP (ANZUP 1603)](https://onco.cc/trials/therap/), [This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.](https://onco.cc/trials/nct07649122/), [This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En](https://onco.cc/trials/nct07028853/), [Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy](https://onco.cc/trials/nct00129142/), [Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging](https://onco.cc/trials/nct04423211/), [Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer](https://onco.cc/trials/nct00104741/), [TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma](https://onco.cc/trials/nct04969315/), [TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ](https://onco.cc/trials/nct07190300/), [Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial](https://onco.cc/trials/nct04513717/), [VISION](https://onco.cc/trials/vision/), [XALute](https://onco.cc/trials/xalute/), [ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct04986423/)
- people: [A. Oliver Sartor](https://onco.cc/people/oliver-sartor/), [Amar U. Kishan](https://onco.cc/people/amar-kishan/), [Andrew J. Armstrong](https://onco.cc/people/andrew-armstrong/), [Andrew Little](https://onco.cc/people/andrew-little/), [Anthony L. Zietman](https://onco.cc/people/anthony-zietman/), [Anthony V. D'Amico](https://onco.cc/people/anthony-damico/), [Arul M. Chinnaiyan](https://onco.cc/people/arul-chinnaiyan/), [Barbara Jereczek-Fossa](https://onco.cc/people/barbara-jereczek-fossa/), [Brasil Silva Neto](https://onco.cc/people/brasil-silva-neto/), [Charles L. Sawyers](https://onco.cc/people/charles-sawyers/), [Chris C. Parker](https://onco.cc/people/chris-parker/), [Christopher J. Sweeney](https://onco.cc/people/christopher-sweeney/), [Clemens Kratochwil](https://onco.cc/people/clemens-kratochwil/), [Daniel E. Spratt](https://onco.cc/people/daniel-spratt/), [Daniel M. Aebersold](https://onco.cc/people/daniel-aebersold/), [David Dearnaley](https://onco.cc/people/david-dearnaley/), [David H. Koch](https://onco.cc/people/david-koch/), [Deborah Watkins Bruner](https://onco.cc/people/deborah-bruner/), [Declan G. Murphy](https://onco.cc/people/declan-murphy/), [Dingwei Ye](https://onco.cc/people/ye-dingwei/), [Eliezer M. Van Allen](https://onco.cc/people/eliezer-van-allen/), [Eric A. Klein](https://onco.cc/people/eric-klein/), [Eric J. Small](https://onco.cc/people/eric-small/), [Fred Saad](https://onco.cc/people/fred-saad/), [Freddie C. Hamdy](https://onco.cc/people/freddie-hamdy/), [Georges-Pascal Haber](https://onco.cc/people/georges-pascal-haber/), [Gerhardt Attard](https://onco.cc/people/gerhardt-attard/), [Harry J. de Koning](https://onco.cc/people/harry-de-koning/), [Hashim U. Ahmed](https://onco.cc/people/hashim-ahmed/), [Howard I. Scher](https://onco.cc/people/howard-scher/), [Ian Davis](https://onco.cc/people/ian-davis/), [Ian F. Tannock](https://onco.cc/people/ian-tannock/), [Jae Lyun Lee](https://onco.cc/people/lee-jae-lyun/), [James L. Gulley](https://onco.cc/people/james-gulley/), [Jeremie Calais](https://onco.cc/people/jeremie-calais/), [Johann de Bono](https://onco.cc/people/johann-de-bono/), [Johannes Czernin](https://onco.cc/people/johannes-czernin/), [Karen E. Knudsen](https://onco.cc/people/karen-knudsen/), [Karim Fizazi](https://onco.cc/people/karim-fizazi/), [Ken Herrmann](https://onco.cc/people/ken-herrmann/), [Kim N. Chi](https://onco.cc/people/kim-chi/), [Louise Emmett](https://onco.cc/people/louise-emmett/), [Maha Hussain](https://onco.cc/people/maha-hussain/), [Mahesh K. B. Parmar](https://onco.cc/people/mahesh-parmar/), [Mark Emberton](https://onco.cc/people/mark-emberton/), [Markus Graefen](https://onco.cc/people/markus-graefen/), [Matthew R. Smith](https://onco.cc/people/matthew-smith/), [Michael Hofman](https://onco.cc/people/hofman-michael/), [Michael J. Morris](https://onco.cc/people/michael-morris/), [Michael Milken](https://onco.cc/people/michael-milken/), [Neeraj Agarwal](https://onco.cc/people/neeraj-agarwal/), [Nicholas James](https://onco.cc/people/nicholas-james/), [Owen N. Witte](https://onco.cc/people/owen-witte/), [Padmanee Sharma](https://onco.cc/people/padmanee-sharma/), [Paola Anna Erba](https://onco.cc/people/paola-anna-erba/), [Peter Bartenstein](https://onco.cc/people/peter-bartenstein/), [Primo N. Lara Jr.](https://onco.cc/people/primo-lara/), [Rahul Aggarwal](https://onco.cc/people/rahul-aggarwal/), [Ramon E. Parsons](https://onco.cc/people/ramon-parsons/), [Rana McKay](https://onco.cc/people/rana-mckay/), [Richard P. Baum](https://onco.cc/people/richard-baum/), [Richard Rogel](https://onco.cc/people/richard-rogel/), [Robert A. Gatenby](https://onco.cc/people/robert-gatenby/), [Samantha Oakes](https://onco.cc/people/samantha-oakes/), [Shahneen Sandhu](https://onco.cc/people/sandhu-shahneen/), [Shahrokh F. Shariat](https://onco.cc/people/shahrokh-f-shariat/), [Shankar Siva](https://onco.cc/people/shankar-siva/), [Silke Gillessen](https://onco.cc/people/silke-gillessen/), [Sir Chris Hoy](https://onco.cc/people/chris-hoy/), [Stephen J. Freedland](https://onco.cc/people/stephen-freedland/), [Susan Clark](https://onco.cc/people/susan-clark/), [Thomas A. Hope](https://onco.cc/people/thomas-hope/), [Thomas J. Fuchs](https://onco.cc/people/thomas-fuchs/), [William G. Nelson](https://onco.cc/people/william-nelson/)
- journals: [Clinical genitourinary cancer](https://onco.cc/journals/clinical-genitourinary-cancer/), [Endocrine-related cancer](https://onco.cc/journals/endocrine-related-cancer/), [European Urology](https://onco.cc/journals/european-urology/), [European Urology Oncology](https://onco.cc/journals/european-urology-oncology/), [Prostate cancer and prostatic diseases](https://onco.cc/journals/prostate-cancer-and-prostatic-diseases/), [Urologic oncology](https://onco.cc/journals/urologic-oncology/)
- ideas: [A multi-cancer platform trial of adaptive (dose-holiday) therapy](https://onco.cc/ideas/idea-bio1-adaptive-therapy-platform/), [A pragmatic trial network for intraoperative margin tools, paid on margin reduction](https://onco.cc/ideas/idea-fund-intraoperative-imaging-trials/), [A public fund and label pathway to trial generic drugs against cancer](https://onco.cc/ideas/idea-moon-generics-for-cancer-fund/), [A regulatory endpoint for drugs that block spread, not tumours](https://onco.cc/ideas/idea-bio2-antimetastatic-endpoint/), [A short pre-surgery drug window as the default early test of new agents](https://onco.cc/ideas/idea-tr1-window-of-opportunity-default/), [A standing platform trial for every major cancer, funded as infrastructure](https://onco.cc/ideas/idea-tr1-standing-platform-per-cancer/), [A test to tell true oligometastatic disease from hidden widespread spread](https://onco.cc/ideas/idea-bio2-oligometastatic-signature/), [A video-based surgical quality registry linking assessed skill to cancer outcomes](https://onco.cc/ideas/idea-fund-surgical-video-registry/), [Alpha-emitting PSMA therapy at first metastatic diagnosis](https://onco.cc/ideas/idea-alpha-first-mhspc/), [An international body to rename indolent lesions so 'cancer' means something](https://onco.cc/ideas/idea-prev-indolent-lesion-nomenclature-body/), [An organotropism atlas that predicts where a cancer will spread](https://onco.cc/ideas/idea-bio2-organotropism-atlas/), [Automatic germline testing for every cancer type where it changes care](https://onco.cc/ideas/idea-prev-reflex-germline-testing/), [Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models](https://onco.cc/ideas/idea-moon-closed-loop-adaptive-therapy/), [Cardiometabolic screening and treatment for survivors on long-term hormone therapy](https://onco.cc/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/), [Certified decision aids required for every preference-sensitive cancer decision](https://onco.cc/ideas/idea-moon-certified-decision-aids/), [Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs](https://onco.cc/ideas/idea-bio2-ctc-clearance-go-nogo/), [Coverage-with-evidence registries for MR-guided and adaptive radiotherapy](https://onco.cc/ideas/idea-fund-adaptive-radiotherapy-evidence/), [Cut the nerve supply to tumours with old drugs](https://onco.cc/ideas/idea-nerve-tumour-blockade/), [Decision aids built into the record for every preference-sensitive cancer choice](https://onco.cc/ideas/idea-acc-embedded-decision-aids/), [Destroy the truncated androgen receptor that hormone drugs cannot touch](https://onco.cc/ideas/idea-bio1-arv7-degrader/), [Detect tumours changing cell type from RNA in the blood](https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/), [Device-agnostic public trials of ablation technologies against surgery](https://onco.cc/ideas/idea-fund-ablation-versus-surgery-trials/), [Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells](https://onco.cc/ideas/idea-moon-dormancy-eradication-programme/), [Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials](https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/), [Fix the neutrophil count rule that excludes many people of African ancestry](https://onco.cc/ideas/idea-tr1-duffy-null-neutrophil-threshold/), [Grow blood-borne tumour cells to test drugs on the cells that actually spread](https://onco.cc/ideas/idea-bio2-ctc-culture-functional-testing/), [Grow models from tumour cells in the blood when a biopsy is impossible](https://onco.cc/ideas/idea-bio1-ctc-derived-explants/), [Keep dormant cells asleep instead of trying to kill them](https://onco.cc/ideas/idea-bio2-pro-dormancy-therapy/), [Keep them asleep: dormancy maintenance as adjuvant therapy](https://onco.cc/ideas/idea-dormancy-maintenance-therapy/), [Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours](https://onco.cc/ideas/idea-moon-cold-to-hot-programme/), [Make one-week radiotherapy the default in overloaded systems](https://onco.cc/ideas/idea-acc-hypofractionation-default-lmic/), [Mandatory staged registries for new surgical techniques before wide adoption](https://onco.cc/ideas/idea-fund-device-technique-registry/), [Modern autopsy studies to measure how much silent cancer people carry](https://onco.cc/ideas/idea-prev-modern-autopsy-reservoir-studies/), [Molecular indolence classifiers bundled with every screening programme](https://onco.cc/ideas/idea-moon-indolence-classifiers-with-screening/), [MRI-first prostate screening with genetic pre-selection](https://onco.cc/ideas/idea-prev-mri-first-prostate-screening-prs/), [Patent-free open-source development of repurposed and off-patent cancer drugs](https://onco.cc/ideas/idea-fund-open-source-repurposing-leads/), [Pay for a course of radiotherapy, not for each fraction](https://onco.cc/ideas/idea-cost-hypofractionation-payment/), [Pay for supervised exercise the way we pay for drugs](https://onco.cc/ideas/idea-bio2-exercise-reimbursement/), [Pay per course of radiotherapy, not per session, so short courses are not penalised](https://onco.cc/ideas/idea-fund-course-based-radiotherapy-payment/), [Payer-funded trials that omit surgery or radiotherapy in low-risk patients](https://onco.cc/ideas/idea-fund-omission-deescalation-trials/), [Pooled coverage-with-evidence for proton therapy across all centres](https://onco.cc/ideas/idea-fund-proton-coverage-with-evidence/), [Pre-consented cohorts that can be randomised to future trials (TwiCs)](https://onco.cc/ideas/idea-tr1-pre-consented-cohort-randomisation/), [Prescribe a quarter dose of abiraterone with breakfast](https://onco.cc/ideas/idea-cost-low-dose-abiraterone-food/), [Prostate active surveillance without scheduled biopsies: MRI and blood tests decide](https://onco.cc/ideas/idea-prev-prostate-as-triggered-biopsy/), [PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer](https://onco.cc/ideas/idea-psma-pet-guided-mdt/), [Qualify PSMA PET tumour volume as a validated imaging biomarker](https://onco.cc/ideas/idea-tr2-psma-volume-qualification/), [Real-time margin assessment and image-guided surgery as the global standard](https://onco.cc/ideas/idea-moon-image-guided-surgery-everywhere/), [Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry](https://onco.cc/ideas/idea-acc-risk-stratified-follow-up/), [Rotate between drugs on a fixed schedule instead of waiting for failure](https://onco.cc/ideas/idea-bio1-alternating-schedules/), [Sexual health assessed and treated as a standard toxicity domain](https://onco.cc/ideas/idea-moon-sexual-health-as-toxicity-domain/), [SMART designs to test treatment strategies, not just single drugs](https://onco.cc/ideas/idea-tr1-smart-designs-for-adaptive-strategies/), [Structured exercise prescribed like a drug in all curative-intent cancer care](https://onco.cc/ideas/idea-exercise-as-adjuvant/), [Test whether calling Gleason 6 'not cancer' changes what men choose](https://onco.cc/ideas/idea-prev-gleason6-terminology-rct/), [Total-body PET for personalised radioligand dosing](https://onco.cc/ideas/idea-total-body-pet-dosimetry/), [Use a hypoxia scan to pick patients for adenosine-pathway drugs](https://onco.cc/ideas/idea-bio2-hypoxia-guided-adenosine/), [Use a polygenic risk score to set when screening starts](https://onco.cc/ideas/idea-prev-prs-screening-start-age/), [Use food effects to cut the dose and cost of oral drugs that absorb better with meals](https://onco.cc/ideas/idea-tr1-food-effect-dose-reduction/), [Use LET, RBE and alpha/beta to decide when protons beat IMRT](https://onco.cc/ideas/idea-bio2-let-rbe-ab-selects-protons/), [What decides which disseminated cells ever colonise?](https://onco.cc/ideas/idea-dtc-colonisation-determinants/), [When the blood test is positive, hunt for the lesion with sensitive imaging](https://onco.cc/ideas/idea-bio2-localise-the-mrd/), [Which patients' blood clones will become leukaemia after treatment?](https://onco.cc/ideas/idea-chip-risk-modifiers/)
- key papers: [Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers](https://onco.cc/key-papers/paper-bray-globocan-2018-cacancer-2018/), [Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial](https://onco.cc/key-papers/paper-psma-prerp-hope-jama-oncol-2021/), [Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report](https://onco.cc/key-papers/paper-powderly-fenbendazole-ivermectin-liver-injury-2026/), [PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)](https://onco.cc/key-papers/paper-partiqol-astro-2024/), [Siegel 2023: Cancer statistics, 2023](https://onco.cc/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/), [Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report](https://onco.cc/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/), [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews](https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/), [Use of alternative medicine for cancer and its impact on survival](https://onco.cc/key-papers/paper-johnson-alternative-medicine-jnci-2018/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://onco.cc/key-papers/paper-vision-nejm-2021/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/), [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- biomarkers: [AR-V7 splice variant](https://onco.cc/biomarkers/ar-v7-splice-variant/), [PSMA expression by PET (PSMA-positive)](https://onco.cc/biomarkers/psma-pet-expression/), [PTEN alteration (sequencing) and PTEN loss (IHC)](https://onco.cc/biomarkers/pten-alteration/)
- cancers: [Biochemical recurrence of prostate cancer](https://onco.cc/cancers/prostate-bcr/), [Localised prostate cancer, high and very high risk](https://onco.cc/cancers/prostate-high-risk/), [Localised prostate cancer, intermediate risk](https://onco.cc/cancers/prostate-intermediate-risk/), [Localised prostate cancer, very low and low risk](https://onco.cc/cancers/prostate-low-risk/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Neuroendocrine and small-cell prostate cancer](https://onco.cc/cancers/prostate-nepc/), [Non-metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-nmcrpc/)

---
JSON: https://onco.cc/api/v1/entities/prostate.json